Finally sofosbuvir: an oral anti-HCV drug with wide performance capability

References

• HopeVDEramovaICapurroDPrevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade AssociationEpidemiol Infect201414227028623714072
   PubMed Web of Science ®Google Scholar
• NaggieSPatelKMcHutchisonJHepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitorsJ Antimicrob Chemother2010652063206920688770
   PubMed Web of Science ®Google Scholar
• KayaliZLabrecqueDRSchmidtWNTreatment of hepatitis C cryoglobulinemia: mission and challengesCurr Treat Options Gastroenterol2006949750717081483
   PubMedGoogle Scholar
• HoofnagleJHHepatitis C: the clinical spectrum of diseaseHepatology199726S15S20
   PubMed Web of Science ®Google Scholar
• RosenHRChronic hepatitis C infectionN Engl J Med20113642429243821696309
   PubMed Web of Science ®Google Scholar
• LindenbachBDRiceCMUnravelling hepatitis C virus replication from genome to functionNature200543693393816107832
   PubMed Web of Science ®Google Scholar
• MajorMEFeinstoneSMThe molecular virology of hepatitis CHepatology199725152715389185778
   PubMed Web of Science ®Google Scholar
• BartenschlagerRLohmannVReplication of hepatitis C virusJ Gen Virol2000811631164810859368
   PubMed Web of Science ®Google Scholar
• LindenbachBDEvansMJSyderAJComplete replication of hepatitis C virus in cell cultureScience200530962362615947137
   PubMed Web of Science ®Google Scholar
• SimmondsPHolmesECChaTAClassification of hepatitis C virus into 6 major genotypes and a series of subtypes by phylogenetic analysis of the Ns-5 regionJ Gen Virol199374239123998245854
   PubMed Web of Science ®Google Scholar
• DomingoEHollandJJRNA virus mutations and fitness for survivalAnnu Rev Microbiol1997511511789343347
   PubMed Web of Science ®Google Scholar
• BlightKJMcKeatingJARiceCMHighly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replicationJ Virol200276130011301412438626
   PubMed Web of Science ®Google Scholar
• LohmannVKornerFKochJOReplication of subgenomic hepatitis C virus RNAs in a hepatoma cell lineScience199928511011310390360
   PubMed Web of Science ®Google Scholar
• PietschmannTLohmannVRutterGCharacterization of cell lines carrying self-replicating hepatitis C virus RNAsJ Virol2001751252126411152498
   PubMed Web of Science ®Google Scholar
• HinrichsenHBenhamouYWedemeyerHShort-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patientsGastroenterology20041271347135515521004
   PubMed Web of Science ®Google Scholar
• HoofnagleJHMullenKDJonesDBTreatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary reportN Engl J Med1986315157515783097544
   PubMed Web of Science ®Google Scholar
• Martinot-PeignouxMSternCMaylinSTwelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirinHepatology2010511122112620069649
   PubMed Web of Science ®Google Scholar
• JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic hepatitis C virus infectionN Engl J Med20113642405241621696307
   PubMed Web of Science ®Google Scholar
• PoordadFMcConeJJrBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med20113641195120621449783
   PubMed Web of Science ®Google Scholar
• ShermanKEFlammSLAfdhalNHResponse-guided telaprevir combination treatment for hepatitis C virus infectionN Engl J Med20113651014102421916639
   PubMed Web of Science ®Google Scholar
• McHutchisonJGMannsMPMuirAJTelaprevir for previously treated chronic HCV infectionN Engl J Med20103621292130320375406
   PubMed Web of Science ®Google Scholar
• MuirAJPoordadFFMcHutchisonJGRetreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment responseHepatology2011541538154622045671
   PubMed Web of Science ®Google Scholar
• BaconBRGordonSCLawitzEBoceprevir for previously treated chronic HCV genotype 1 infectionN Engl J Med20113641207121721449784
   PubMed Web of Science ®Google Scholar
• ThompsonAJMuirAJSulkowskiMSInterleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusGastroenterology201013912017820399780
   PubMed Web of Science ®Google Scholar
• KozielMJPetersMGViral hepatitis in HIV infectionN Engl J Med20073561445145417409326
   PubMed Web of Science ®Google Scholar
• SorianoVPetersMGZeuzemSNew therapies for hepatitis C virus infectionClin Infect Dis20094831332019123867
   PubMed Web of Science ®Google Scholar
• SarrazinCZeuzemSResistance to direct antiviral agents in patients with hepatitis C virus infectionGastroenterology201013844746220006612
   PubMed Web of Science ®Google Scholar
• MigliaccioGTomassiniJECarrollSSCharacterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitroJ Biol Chem2003278491644917012966103
   PubMed Web of Science ®Google Scholar
• LamAMEspirituCBansalSGenotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virusAntimicrob Agents Chemother2012563359336822430955
   PubMed Web of Science ®Google Scholar
• CarrollSSLudmererSHandtLRobust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzeesAntimicrob Agents Chemother20095392693419075052
   PubMed Web of Science ®Google Scholar
• GaneEJStedmanCAHylandRHNucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis CN Engl J Med2013368344423281974
   PubMed Web of Science ®Google Scholar
• LawitzEPoordadFFPangPSSofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialLancet201438351552324209977
   PubMed Web of Science ®Google Scholar
• NelsonDRZeuzemSAndreonePBalapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsAnn Hepatol201211153122166557
   PubMed Web of Science ®Google Scholar
• PockrosPJensenDTsaiNFirst SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trialJ Hepatol201154S538S538
   PubMed Web of Science ®Google Scholar
• PawlotskyJMNajeraIJacobsonIResistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymeraseAntivir Ther20121741142322402762
   PubMed Web of Science ®Google Scholar
• GaneEJRobertsSKStedmanCAMOral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialLancet20103761467147520951424
   PubMed Web of Science ®Google Scholar
• PawlotskyJMTreatment failure and resistance with direct-acting antiviral drugs against hepatitis C virusHepatology2011531742175121374691
   PubMed Web of Science ®Google Scholar
• SchmidtWNNelsonDRPawlotskyJMDirect acting antiviral agents and the path to interferon independenceClin Gastroenterol Hepatol201412572873723872239
   PubMed Web of Science ®Google Scholar
• SusserSWelschCWangYLCharacterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patientsHepatology2009501709171819787809
   PubMed Web of Science ®Google Scholar
• BartenschlagerRLohmannVPeninFThe molecular and structural basis of advanced antiviral therapy for hepatitis C virus infectionNat Rev Microbiol20131148249623748342
   PubMed Web of Science ®Google Scholar
• KiefferTLSarrazinCMillerJSTelaprevir and pegylated interferon-alpha–2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsHepatology20074663163917680654
   PubMed Web of Science ®Google Scholar
• Targett-AdamsPGrahamEJMiddletonJSmall molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of actionJ Virol2011856353636821507963
   PubMed Web of Science ®Google Scholar
• GaoMNettlesREBelemaMChemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature20104659610820410884
   PubMed Web of Science ®Google Scholar
• WangCFHuangHCValeraLHepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052Antimicrob Agents Chemother2012561350135822214777
   PubMed Web of Science ®Google Scholar
• JacobsonIMGordonSCKowdleyKVSofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment optionsN Engl J Med2013368201867187723607593
   PubMed Web of Science ®Google Scholar
• LawitzEMangiaAWylesDSofosbuvir for previously untreated chronic hepatitis C infectionN Engl J Med20133681878188723607594
   PubMed Web of Science ®Google Scholar
• MurakamiETolstykhTBaoHMechanism of activation of PSI-7851 and its diastereoisomer PSI-7977J Biol Chem2010285343373434720801890
   PubMed Web of Science ®Google Scholar
• LamAMMurakamiEEspirituCPSI–7851, a pronucleotide of beta-D–2′-deoxy–2′-fluoro–2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis c virus replicationAntimicrob Agents Chemother2010543187319620516278
   PubMed Web of Science ®Google Scholar
• DavisGLEsteban-MurRRustgiVInterferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy GroupN Engl J Med1998339149314999819447
   PubMed Web of Science ®Google Scholar
• OsinusiAMeissnerEGLeeYJSofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics a randomized clinical trialJAMA201331080481123982366
   PubMed Web of Science ®Google Scholar
• ZeuzemSDusheikoGMSalupereRSofosbuvir plus ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trialHepatology201358733a734a
   Web of Science ®Google Scholar
• JacobsonIMGhalibRHRodriguez-TorresMSVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS studyHepatology2013581379a1380a
   Web of Science ®Google Scholar
• SulkowskiMSGardinerDFRodriguez-TorresMDaclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionN Engl J Med201437021122124428467
   PubMed Web of Science ®Google Scholar
• AfdhalNReddyKRNelsonDRLedipasvir and sofosbuvir for previously treated HCV genotype 1 infectionN Engl J Med20143701483149324725238
   PubMed Web of Science ®Google Scholar
• AfdhalNZeuzemSKwoPLedipasvir and sofosbuvir for untreated HCV genotype 1 infectionN Engl J Med20143701889189824725239
   PubMed Web of Science ®Google Scholar
• KowdleyKVGordonSCReddyKRLedipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisN Engl J Med20143701889189824725239
   PubMed Web of Science ®Google Scholar
• GaneEJHylandRHAnDSofosbuvir/Ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior Sofosbuvir treatment experienceJ Hepatol201460S3
   Web of Science ®Google Scholar
• NaggieSSulkowskiMLalezariJSofosbuvir plus ribavirin for HCV genotype 1–3 infection in HIV coinfected patients (PHOTON-1)Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston, MA, USA Abstract 26
   Google Scholar
• CurryMPFornsXChungRTPretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantationHepatology201358314a315a23424168
   PubMed Web of Science ®Google Scholar
• CharltonMRGaneEJMannsMPSofosbuvir and ribavirin for the treatment of established recurrent hepatitis c infection after liver transplantation: preliminary results of a prospective, multicenter studyHepatology2013581378a1378a
   Web of Science ®Google Scholar
• KoffRSReview article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infectionAliment Pharmacol Ther20143947848724387618
   PubMed Web of Science ®Google Scholar
• KarageorgopoulosDEEl-SherifOBhaganiSDrug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfectionCurr Opin Infect Dis201427364524305043
   PubMed Web of Science ®Google Scholar
• SulkowskiMJacobsonIMGhalibROnce-daily Simeprevir (TMC435) plus Sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with METAVIR FO-2: COSMOS Study subgroup analysisJ Hepatol201460S4
   Web of Science ®Google Scholar
• LawitzEGhalibRRodriguez-TorresMSimeprevir plus sofos-buvir with/without ribavirin in HCV genotype-1 prior null-responder/treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3–4 (Cohort 2)J Hepatol201460S524
   Web of Science ®Google Scholar
• Sofosbuvir for Treatment of Chronic Hepatitis C Infection, Antiviral Drugs Advisory Committee Meeting Briefing DocumentGilead Sciences, Inc2013 Available from: http://www.natap.org/2013/HCV/20131025-AVDAC-B1-02-Gilead.pdfAccessed August 25, 2014
   Google Scholar